Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

BACKGROUND: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. OBJECTIVE: The purpose of this study was to evaluate in a prospective ob...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:United European Gastroenterol J
Hlavní autoři: Guidi, Luisa, Pugliese, Daniela, Tonucci, Tommaso Panici, Bertani, Lorenzo, Costa, Francesco, Privitera, Giuseppe, Tolusso, Barbara, Di Mario, Clara, Albano, Eleonora, Tapete, Gherardo, Gremese, Elisa, Papa, Alfredo, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Armuzzi, Alessandro
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826518/
https://ncbi.nlm.nih.gov/pubmed/31700632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619873784
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky